BIAF Stock Overview
Engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
bioAffinity Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.22 |
| 52 Week High | US$3.62 |
| 52 Week Low | US$1.20 |
| Beta | 3.12 |
| 11 Month Change | -15.86% |
| 3 Month Change | -29.19% |
| 1 Year Change | -12.86% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.30% |
Recent News & Updates
Shareholder Returns
| BIAF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.9% | -3.7% | 0.3% |
| 1Y | -12.9% | 15.2% | 31.1% |
Return vs Industry: BIAF underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: BIAF underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| BIAF volatility | |
|---|---|
| BIAF Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIAF's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BIAF's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 75 | Maria Zannes | www.bioaffinitytech.com |
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc. Fundamentals Summary
| BIAF fundamental statistics | |
|---|---|
| Market cap | US$19.25m |
| Earnings (TTM) | -US$8.45m |
| Revenue (TTM) | US$9.37m |
2.0x
P/S Ratio-2.3x
P/E RatioIs BIAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIAF income statement (TTM) | |
|---|---|
| Revenue | US$9.37m |
| Cost of Revenue | US$6.09m |
| Gross Profit | US$3.28m |
| Other Expenses | US$11.73m |
| Earnings | -US$8.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 35.03% |
| Net Profit Margin | -90.16% |
| Debt/Equity Ratio | 9.3% |
How did BIAF perform over the long term?
See historical performance and comparison